↓ Skip to main content

Michigan Publishing

Article Metrics

Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a…

Overview of attention for article published in Journal of Biotechnology, October 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#2 of 2,824)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
71 news outlets
twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
19 Mendeley
Title
Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a Clinical Study
Published in
Journal of Biotechnology, October 2016
DOI 10.1016/j.jbiotec.2016.10.010
Pubmed ID
Authors

Mahesh Kudrimoti, Amarintha Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Jenna Elder, Stephen T. Sonis, Richard Straube, Oreola Donini, Kudrimoti, Mahesh, Curtis, Amarintha, Azawi, Samar, Worden, Francis, Katz, Sanford, Adkins, Douglas, Bonomi, Marcelo, Elder, Jenna, Sonis, Stephen T, Straube, Richard, Donini, Oreola

Abstract

Dusquetide, a novel Innate Defense Regulator, modulates the innate immune system at a key convergence point in intracellular signaling pathways and has demonstrated activity in both reducing inflammation and increasing clearance of bacterial infection. Innate immunity has also been implicated in the pathogenesis of oral mucositis (OM), a universal toxicity of chemoradiation therapy (CRT). Testing the hypothesis that dusquetide can mitigate the development and duration of OM, preclinical studies have been completed and correlated with interim results from a Phase 2 clinical study in patients undergoing CRT for head and neck cancer. Dusquetide reduced the duration of OM in mouse and hamster models by approximately 50%, which was recapitulated by the 50% reduction of severe OM (SOM) in the Phase 2 trial. A reduction in the clinical rate of infection was also observed, consistent with previously reported preclinical studies. In aggregate, these results not only demonstrate the safety and efficacy of dusquetide in addressing this unmet medical need, but also provide proof of concept for the translation of dusquetide action between animal models and the human clinical setting, and further support the contention that innate immunity is an important driver for the initiation and continued impact of OM.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 4 21%
Student > Master 3 16%
Researcher 3 16%
Student > Bachelor 2 11%
Student > Postgraduate 2 11%
Other 5 26%
Readers by discipline Count As %
Unspecified 5 26%
Medicine and Dentistry 4 21%
Biochemistry, Genetics and Molecular Biology 3 16%
Agricultural and Biological Sciences 3 16%
Pharmacology, Toxicology and Pharmaceutical Science 2 11%
Other 2 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 551. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2018.
All research outputs
#10,163
of 11,799,729 outputs
Outputs from Journal of Biotechnology
#2
of 2,824 outputs
Outputs of similar age
#710
of 259,783 outputs
Outputs of similar age from Journal of Biotechnology
#1
of 22 outputs
Altmetric has tracked 11,799,729 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,824 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 259,783 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.